STOXPO
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
STOXPO
No Result
View All Result
Home Healthcare Biotechnology
radiology-2

Monopar’s MNPR-101 Radiopharma Program Shows Promise in Targeting Advanced Cancers

byLiliana Vida
February 22, 2024
in Biotechnology, Micro-Cap
Reading Time: 1 min read
Share on TwitterShare on LinkedIn

Monopar Therapeutics (MNPR) has unveiled promising preclinical data for its MNPR-101 radiopharmaceutical program, marking a significant stride in the fight against advanced cancers. The innovative program targets cancers expressing the urokinase plasminogen activator receptor (uPAR), including a majority of triple-negative breast, colorectal, and pancreatic cancers.

The key focus of radiopharmaceutical therapy lies in maximizing the dose delivered to the tumor while minimizing impact on normal tissues. Monopar’s preclinical imaging and therapeutic efficacy data showcase substantial progress in this regard. Through meticulous optimization, the company’s in-house team has achieved heightened tumor uptake of MNPR-101-Zr, as evidenced by positron emission tomography (PET) sequential imaging.

Furthermore, preclinical studies have demonstrated compelling anti-tumor benefits with MNPR-101 conjugated to therapeutic radioisotopes. In both triple-negative breast cancer and pancreatic cancer models, near-complete tumor elimination was observed following a single injection of the radiopharmaceutical agent.

Encouraged by these findings, Monopar has obtained clearance to commence a Phase 1 dosimetry clinical trial for MNPR-101-Zr in advanced cancer patients. Andrew Cittadine, Monopar’s Chief Operating Officer, expressed optimism about the potential clinical benefits highlighted by these preclinical results, signaling a promising avenue in the pursuit of effective cancer treatments.

Previous Post

La Rosa Holdings Expands Reach with Acquisition of Winter Garden Franchisee

Next Post

Ocular Therapeutix Announces Private Placement to Bolster Clinical Development Initiatives

Related Posts

vaccine

Moderna Stock Surges as New Cancer Vaccine Initiative Fuels Investor Optimism

byLuca Blaumann
October 9, 2026
0

Shares jumped after reports of a major public-private effort aimed at accelerating cancer vaccine development Moderna (MRNA) shares surged Friday...

chemistry-2

Kodiak Sciences Soars After Zenkuda Delivers Positive Phase 3 Results

byLuca Blaumann
September 28, 2026
0

KOD shares jumped as much as 90% in premarket trading after the company reported encouraging DAYBREAK data in wet age-related...

Viking Therapeutics Reports Positive VK2735 Maintenance Data as Obesity Drug Advances

byLiliana Vida
September 22, 2026
0

GLP-1/GIP candidate delivers 22% placebo-adjusted weight loss while less-frequent dosing shows potential for maintaining results Viking Therapeutics (VKTX) announced positive...

Next Post
opthalmology

Ocular Therapeutix Announces Private Placement to Bolster Clinical Development Initiatives

Latest News

Qualcomm CEO Rejects AI Market Correction Fears as Company Expands Into Data Centers

D-Wave Quantum Q3 Revenue Climbs 21% as Backlog Surges Over 1,200%

CoreWeave Q3 Revenue Surges Nearly 170% to $3.66 Billion as AI Demand Accelerates

CoreWeave Earnings Preview: Why Guidance Matters More Than Q3 Results

D-Wave Quantum Q3 Revenue Rises 21% as Bookings Surge and Quantum Adoption Expands

Based on Your Interest

Auto Manufacturers

Lucid Secures $1.75 Billion Liquidity Boost From Saudi PIF to Support Turnaround

November 10, 2026
Artificial Intelligence

KULR Technology Revenue Surges 197% in Q3 as Battery Sales Nearly Quadruple

November 10, 2026
investing
Aerospace & Defense

Rocket Lab Q3 Revenue Surges 73% to $268 Million, Beating Wall Street Expectations

November 9, 2026

Recommended

Artificial Intelligence

IonQ Shares Climb as Company Expands Government Reach Through Carahsoft Partnership

November 9, 2026
Aerospace & Defense

AST SpaceMobile and Rakuten Launch Joint Venture Backed by $1 Billion in Japanese Government Funding

November 9, 2026
Aerospace & Defense

SpaceX Secures Reported $45 Billion AI Infrastructure Deal With Anthropic

November 9, 2026
Artificial Intelligence

IonQ Revenue Surges 336% to Record $173.8 Million as Quantum Computing Demand Accelerates

November 6, 2026
Artificial Intelligence

AMD Revenue Surges 45% as AI Demand Drives Record Data Center Growth

November 3, 2026
Stoxpo

Follow us on social media:

Highlights

  • Qualcomm CEO Rejects AI Market Correction Fears as Company Expands Into Data Centers
  • D-Wave Quantum Q3 Revenue Climbs 21% as Backlog Surges Over 1,200%
  • CoreWeave Q3 Revenue Surges Nearly 170% to $3.66 Billion as AI Demand Accelerates
  • CoreWeave Earnings Preview: Why Guidance Matters More Than Q3 Results
  • D-Wave Quantum Q3 Revenue Rises 21% as Bookings Surge and Quantum Adoption Expands

Category

  • Blog
  • Communication Services
    • Entertainment
    • Internet
    • Telecommunications
  • Companies
    • Large-Cap
    • Mega-Cap
    • Micro-Cap
    • Mid-Cap
    • Small-Cap
  • Consumer Cyclical
    • Auto Manufacturers
    • Casinos & Gambling
    • Ground Transportation
    • Hospitality
      • Casinp
      • Resorts & Lodging
      • Restaurants
      • Travel
        • Airlines
    • Retail
    • Textiles, Apparel & Luxury Goods
  • Consumer Defensive
    • Beverages
    • Discount Stores
    • Distributor
    • Ecommerece
    • Electrical Equipment
    • Foods
    • Household & Personal Products
    • Leisure Products
    • Tobacco
  • Contributions
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Economy
  • Energy
    • Electric
    • Oil & Gas
    • Renewables
  • Financial Services
    • Asset Management
    • Banks
    • Brokerages
    • Credit Services
    • Insurance
  • Healthcare
    • Biotechnology
    • Medical Devices
    • Pharmaceuticals
  • Industrials
    • Aerospace & Defense
    • Construction
    • Industrial Machinery
  • Materials
    • Building Materials
    • Chemicals
    • Gold
    • Mining
    • Silver
    • Steel
  • Q&A's
  • Real Estate
  • Technology
    • Artificial Intelligence
    • Computer Hardware
    • Consumer Electronics
    • Cybersecurity
    • IT Services
    • Semiconductors
    • Software
  • Utilities

Latest News

semiconductor-6

Qualcomm CEO Rejects AI Market Correction Fears as Company Expands Into Data Centers

November 12, 2026

D-Wave Quantum Q3 Revenue Climbs 21% as Backlog Surges Over 1,200%

November 11, 2026

CoreWeave Q3 Revenue Surges Nearly 170% to $3.66 Billion as AI Demand Accelerates

November 11, 2026
  • About
  • Privacy Policy
  • Contact

© 2024 All Rights Reserved: STOXPO.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More

In case of sale of your personal information, you may opt out by using the link Do Not Sell My Personal Information

Accept Cookie Settings
Cookies are small text files that can be used by websites to make a user's experience more efficient. The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission. This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.
  • Always Active
    Necessary
    Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
  • Marketing
    Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.
  • Analytics
    Analytics cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.
  • Preferences
    Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.
  • Unclassified
    Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.
Cookie Settings

Do you really wish to opt-out?

No Result
View All Result
  • Latest News
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Technology
    • Software
    • Semiconductors
  • Crypto
    • Bitcoin
    • Ethereum
    • Altcoins
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions

© 2024 All Rights Reserved: STOXPO.